NCT06624618 Rapid Molecular Diagnosis of Sepsis in the Intensive Care Unit
| NCT ID | NCT06624618 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Maastricht University Medical Center |
| Condition | Sepsis |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2024-05-01 |
| Primary Completion | 2026-05-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2024-05-01 with a primary completion date of 2026-05-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Rapid diagnosis of sepsis is crucial for treatment and survival. Currently, blood culture takes 48 hours-5 days to complete. After starting antimicrobial treatment blood culture results are not reliable. As a result, empirical broad spectrum antimicrobial therapy is mostly used. This implies possible antimicrobial over- or under treatment which is associated with increased antimicrobial resistance development. Early identification of the causative pathogen of sepsis will therefore have a major impact on the adequate treatment and reduction of high mortality rates. To date, there is not a single molecular diagnostic test available on the market to detect all putative causative bacterial pathogens of sepsis. In this study, the investigators will develop and validate a completely new molecular sepsis approach based on pathogen DNA detection, as an alternative to culture.
Eligibility Criteria
Inclusion Criteria: -Patients are included when routine blood cultures are ordered for diagnosis of bloodstream infections. Exclusion Criteria: -N/A
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06624618 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Sepsis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06624618 currently recruiting?
Yes, NCT06624618 is actively recruiting participants. Contact the research team at anna.wijen@maastrichtuniversity.nl for enrollment information.
Where is the NCT06624618 trial being conducted?
This trial is being conducted at Maastricht, Netherlands.
Who is sponsoring the NCT06624618 clinical trial?
NCT06624618 is sponsored by Maastricht University Medical Center. The trial plans to enroll 300 participants.